


Samuel H. Pepkowitz, MD, Medical Director
 345 Oyster Point Blvd
 South San Francisco, CA 94080 - Tel: (800) 777-0177

Patient Initials:	DOB	Patient ID/Medical Record #	Gender	Monogram Accession #
Date Collected	Date Received	Date Reported	Mode	Report Status
Investigator			Specimen ID	
Comments:				

DRUG		PHENOSENSE™ SUSCEPTIBILITY				ASSESSMENT
Generic Name	Brand Name	Patient IC50 (µg/mL)	Fold Change	Increasing Drug Susceptibility	Decreasing	Drug
Enfuvirtide	Fuzeon	4.5889	120			ENF Reduced Susc.

Fold Change in IC50 of Patient Virus in relation to distribution of enfuvirtide-naive viral isolates*:



*The susceptibility cutoff for enfuvirtide is at the 99th percentile of the distribution of enfuvirtide phenotypes in a naive reference population. This reference population consisted of baseline isolates from the TORO1 and TORO2 clinical trials. Among these 220 baseline isolates a relatively broad range of enfuvirtide susceptibility was observed (geometric mean fold change = 1.54; 99th percentile: 0.42 - 6.48). The appropriate interpretation of phenotypic test results should take into consideration the natural variability in susceptibility of enfuvirtide-naive viruses and inherent assay variability.

Important Definitions

IC50: Concentration of drug required to inhibit viral replication by 50%.

$$\text{Fold Change} = \frac{\text{IC50 patient}}{\text{IC50 reference}}$$

For more information on interpreting this report, please visit www.MonogramHIV.com or call Customer Service at 800-777-0177 between the hours of 6:30am to 5:00pm PT Monday through Friday.

PhenoSense Entry is a proprietary, recombinant virus, single replication cycle assay which uses gp160 coding regions of HIV-1 from a patient blood sample to evaluate tropism and entry inhibitor susceptibility. The tropism assay and the PhenoSense Entry assay for measurement of IC50-fold change meets the standards for performance characteristics and all other quality control and assurance requirements established by the Clinical Laboratory Improvement Amendments. All other measurements reported for the PhenoSense Entry Assay are provided for information only. The results have been disclosed to you from confidential records protected by law and are not to be disclosed to unauthorized persons. Further disclosure of these results is prohibited without specific consent of the persons to whom it pertains, or as permitted by law.